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Abstract
Lafora Disease (LD) is a fatal neurodegenerative epileptic disorder that presents as a neurological deterioration with the
accumulation of insoluble, intracellular, hyperphosphorylated carbohydrates called Lafora bodies (LBs). LD is caused by
mutations in either the gene encoding laforin or malin. Laforin contains a dual specificity phosphatase domain and a
carbohydrate-binding module, and is a member of the recently described family of glucan phosphatases. In the current
study, we investigated the functional and physiological relevance of laforin dimerization. We purified recombinant human
laforin and subjected the monomer and dimer fractions to denaturing gel electrophoresis, mass spectrometry, phosphatase
assays, protein-protein interaction assays, and glucan binding assays. Our results demonstrate that laforin prevalently exists
as a monomer with a small dimer fraction both in vitro and in vivo. Of mechanistic importance, laforin monomer and dimer
possess equal phosphatase activity, and they both associate with malin and bind glucans to a similar extent. However, we
found differences between the two states’ ability to interact simultaneously with malin and carbohydrates. Furthermore, we
tested other members of the glucan phosphatase family. Cumulatively, our data suggest that laforin monomer is the
dominant form of the protein and that it contains phosphatase activity.
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Introduction
Laforin is a dual specificity phosphatase encoded by the EPM2A
(epilepsy of progressive myoclonus type 2 A) gene [1,2]. Autosomal
recessive mutations in EPM2A cause Lafora disease (LD) [1,2]. LD
is a type of myoclonic epilepsy where the patient undergoes
neurodegeneration and severe cognitive decline. Occurrence of
seizures begins in the second decade of patient’s life and LD results
in fatality within ten years of the first seizure [3,4,5,6].
Pathognomonic insoluble intracellular carbohydrate/glucan de-
posits termed Lafora bodies (LBs) are observed in brain, skeletal
muscle, skin, liver, and other tissues of LD patients [6].
Laforin contains an amino-terminal carbohydrate-binding
module (CBM) belonging to the CBM20 family and a carboxy-
terminal dual specificity phosphatase (DSP) domain [1,2,7,8].
Recombinant laforin hydrolyzes phosphotyrosine and phospho-
serine/threonine substrates in vitro [7,9], but laforin is structurally
most similar to non-proteinaceous DSPs [10]. Studies from our
group and others demonstrate that laforin is a unique phosphatase
in that it binds and dephosphorylates phospho-glucans
[11,12,13,14]. Supporting this finding is the fact that LBs contain
increased amounts of phosphate compared to normal glycogen
[12,15]. A recent report finds that phosphate is incorporated into
glycogen by glycogen synthase as an error during synthesis [16].
Laforin was also shown to dephosphorylate glycogen synthase
kinase-3b (GSK3b) [17,18,19]; however, ourselves and other
groups have not observed dephosphorylation of GSK3b by laforin
[11,12].
Autosomal recessive mutations in the EPM2B gene that encodes
the protein malin also cause LD [20]. We previously demonstrated
that malin is a single-subunit E3 ubiquitin ligase that binds and
ubiquitinates laforin [21]. In addition, multiple labs demonstrated
that laforin functions as a scaffolding protein for the laforin-malin
complex-mediated down regulation of proteins involved in
glycogen metabolism, such as protein targeting to glycogen
(PTG), amylo-1,6-glucosidase,4-alpha-glucanotransferase (AGL/
GDE), and muscle glycogen synthase (GS) [22,23,24,25]. Howev-
er, these results are currently in dispute given recent results
generated from a malin knockout mouse [26,27].
A recent study reported that laforin forms SDS-resistant dimers
both in vitro and in vivo [28]. Surprisingly, it was reported that
laforin dimers possess the vast majority of laforin phosphatase
activity and that monomeric laforin is nearly inactive [28]. Many
proteins undergo self-association to form dimers and oligomers
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and this dimerization gives them structural and functional
advantages [29]. Among phosphatases, dimerization is commonly
observed in receptor protein-tyrosine phosphatases (RPTPs)
[30,31]. Homodimerization of RPTPa-1, CD45, and SAP-1 was
demonstrated to inhibit their activity [31,32,33], whereas
dimerization of RPTPs affected its ligand binding [34]. However,
dimerization of non-receptor PTPs such as that observed in
alkaline phosphatase, bovine protein tyrosine phosphatase, and
vaccinia virus H1 is a rare phenomenon [35,36,37,38,39].
Laforin is a cytoplasmic phosphatase and therefore the
occurrence of laforin dimerization is both intriguing and
applicable in determining the molecular etiology of Lafora
disease. One could envision dimerization affecting glucan-
binding, protein-protein interactions, and/or phosphatase activity
of laforin. In addition, laforin oligomerization could be involved
in the formation of LBs. Proteinaceous accumulations are a
common theme in neurological disorders. Even though LBs are
mainly made up of insoluble glucans, unlike the protein deposits
seen in Alzheimer’s and Parkinson’s disease, it has been suggested
that LD pathology may have a component linked to mis-
regulation of the proteasome [40,41]. However, structural and
functional consequences of laforin dimerization have not been
fully elucidated. Thus, we aimed to define the effect of
dimerization on the function of laforin and its possible role in
the etiology of Lafora disease.
Methods
Plasmids and protein purification
pET21a Hs-laforin-HIS6, pET21a At-SEX4-HIS6(D81),
pET21a Cm-laforin-HIS6, pCDNA3.1NF-malin, and pET-GST-
malin-HIS6 are described in refs [13,21]. pGEX6P1-laforin was
obtained by digesting the corresponding pEG202-laforin plasmid
[25] with BamHI/SalI and subcloning the fragments into
pGEX6P1 (GE Healthcare). Other plasmids used in this study
were pCMVmyc-laforin [25] and pGEX4T1-VHR, a generous
gift of Dr. Rafael Pulido (Centro de Investigacion Principe Felipe,
Valencia, Spain). Dr. Marcelo Sousa generously provided purified
arnA protein. Recombinant proteins were purified from soluble
bacterial lysates in buffer (50 mM Tris pH 8.0, 300 mM NaCl,
0.5% Triton X-100, complete mini protease inhibitor (Roche))
using Ni-NTA resin (Qiagen) followed by gel filtration chroma-
tography using an AKTA Purifier with a HiLoad 16/60 Superdex
75 or a Superdex 200 10/300 GL size exclusion column (GE
Healthcare) as previously described [42].
Protein gel electrophoresis and mass spectrometry
Denatured gel electrophoresis was carried out using NuPAGE
10% Bis-Tris gels. Coomassie-stained bands were cut from gels,
digested with trypsin, desalted, and analyzed by MALDI TOF/
TOF. The peptides were searched with Protein Pilot against Swiss-
Prot database. The mass spectrometric analysis was performed at
the University of Kentucky, Center for Structural Biology Protein
Core Facility.
Phosphatase activity measurements
para-nitrophenylphosphate (pNPP, 50 mM)/3-O-methyl fluo-
rescein phosphate (OMFP, 0.5 mM) and amylopectin (0.9 mg/ml)
were used to determine phosphatase activity of Hs-laforin, Cm-
laforin, and SEX4. Assays were performed as previously
described [13]. Briefly, reactions were carried out in buffer
containing 0.1 M sodium acetate, 0.05 M bis-Tris, 0.05 M Tris-
HCl, 2 mM dithiothreitol, pH 6.0 for pNPP assay or in buffer
(0.1 M Tris-HCl pH 8, 40 mM NaCl, 2 mM DTT) for OMFP
assay. The absorbance of the product was measured at 410 nm
for pNPP assay and at 490 nM for OMFP assay. Phosphatase
activity using amylopectin and malachite green reagent was
measured at 620 nm as described previously [11]. The reaction
used 45 mg of amylopectin as a substrate and the same buffer as
used in pNPP assay. The reaction was terminated by addition of
0.1 M N-ethylmaleimide prior to the addition of malachite green
reagent.
Cell culture and immunodetection
Human embryonic kidney (HEK293) cells were grown in
DMEM (Lonza) supplemented with 100 units/ml penicillin,
100 mg/ml streptomycin, 2 mM glutamine, 10% inactivated fetal
bovine serum (GIBCO). 1.56106 cells were plated onto 60 mm
culture dishes the day before transfection. Cells were transfected
with 1 mg of pCMVmyc-laforin plasmid using Lipofectamine 2000
(Invitrogen). Twenty-four hours after transfection, cells were
scraped on ice in lysis buffer [10 mM TrisHCl pH 8; 150 mM
NaCl, 15 mM EDTA; 0.6 M sucrose, 0.5% nonidet P-40 (NP-40),
protease inhibitor cocktail (Roche), 1 mM PMSF, 50 mM NaF
and 5 mM Na2P2O7]. Cells were lysed by repeated passage
through a 25-gauge needle. To analyze proteins under non-
reducing conditions, cell extracts (25 mg) were diluted in SDS- and
DTT-free loading buffer (125 mM Tris-HCl, 20% glycerol) and
analyzed by regular SDS-PAGE and immunoblotting using an
anti-myc (Sigma) antibody.
Glucan-binding assay
Glucan-binding assays were performed as previously described
[7]. Briefly, laforin monomer and dimer, normalized to laforin
content, were incubated with amylopectin (5 mg) suspended in
0.5 ml of buffer containing 50 mM Tris, 150 mM NaCl, pH 7.5
for an hour at 4u C. Co-sedimentation with amylopectin was
measured by centrifuging the samples at 1060006g for 1.5 hrs and
analyzing the supernatant and pellet fractions thus obtained by
immunoblotting with anti-HIS6 antibody. For testing the effect of
malin on glucan-binding ability of laforin, purified HIS6-GST-
malin was added to laforin monomer and dimer along with
amylopectin and same method was followed with use of mouse
monoclonal antibody to detect laforin (Abnova).
Immunoprecipitations
HEK293 cells were transfected with FLAG-tagged malin using
Lipofectamine 2000 (Invitrogen) as above. Cells were lysed using
modified RIPA buffer (Tris pH 8.0 50 mM, NaCl 150 mM, NP40
1%, glycerol 10%, NaF 10 mM, and EDTA 0.4 mM). FLAG-
malin was immunoprecipitated with anti-FLAG M2 agarose beads
(Sigma), the beads were washed twice with modified RIPA buffer,
and then incubated with laforin monomer or dimer for 1 hr at 4u
C. Following this incubation, the beads were washed once with
modified RIPA buffer and proteins were eluted with 50 ml of 26
NuPage sample buffer (Invitrogen) at 95uC. Western analysis was
used to detect laforin with a rabbit polyclonal antibody (GeneTex)
and an anti-FLAG-HRP antibody (Sigma) to detect malin.
Statistical analysis
Values are given as means 6 SEM of at least three independent
experiments. Differences between groups are analyzed by two-
tailed student’s t-tests or by one-way analysis of variances. The
significance has been considered at * p,0.05 and ** p,0.001, as
indicated in each case. Data for protein purification, gel
electrophoresis, glucan-binding, and immunoprecipitation is
representative of al least three independent determinations.
Monomeric Laforin Is an Active Phosphatase
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Results
Monomeric laforin is the dominant species
As previously reported by Liu et al. [28], size exclusion
chromatography of purified Hs-laforin-HIS6 expressed in bacteria
results in two prominent peaks, laforin dimer (peak A) and laforin
monomer (peak B) (Figure 1A). To evaluate if we had fully
resolved these peaks, we collected the fractions from peak B in
Figure 1A, combined the fractions, concentrated them, and passed
over the same size exclusion column. As expected, peak B
produced a single peak (Figure 1B). These results demonstrate that
the two peaks are distinct and that the monomer fraction does not
convert into a dimer.
Resolving the constituents of these peaks by gel electrophoresis
under fully denaturing conditions revealed that the monomeric
peak (peak B) is highly pure and present at the expected 37 kDa
band. However, the dimeric peak (peak A) showed a single band at
37 kDa and three defined bands around 75 kDa (Figure 1C). To
determine the identity of the proteins, we performed mass
spectrometry on each band. In the peak B fraction, laforin was
the only protein identified. As expected under denatured
conditions, peak A also contained laforin at 37 kDa. However,
peak A also contained the E. coli proteins arnA, Hsp70, and
GroEL as well as laforin at around 75 kDa, of which arnA was the
predominant band (Figure 1D). Although only a fraction of the
lower band in the 75 kDa range was laforin, we were surprised to
find some dimeric laforin resistant to fully reduced and denatured
conditions. However, the majority of dimeric laforin is converted
to a monomer when subjected to high levels of reducing agent,
SDS, and boiling.
Our mass spectrometry results identified arnA as the major
contaminant in the dimeric fraction A (Figure 1). arnA is a bi-
functional polymyxin-resistant protein that catalyzes oxidative
decarboxylation of UDP-Glucuronic acid and formylation of
UDP-Ara4N [43]. The Coomassie-stained gel and mass spec-
trometry results demonstrate that approximately 50% of the
proteins in fraction A are not laforin. A previous report suggested
that the laforin dimer was fully resistant to denaturation by heat
and SDS treatment [28]. However, our results demonstrate that
the major band in the 75 kDa range is E. coli arnA, and that the
vast majority of laforin in peak A is denatured and runs as a
37 kDa species. Importantly, these results confirm that laforin does
form dimers, but only a minor fraction of recombinant laforin
dimerizes. In addition, the dimer fraction (peak A) is contaminated
with E. coli proteins.
Laforin monomer and dimer have equal phosphatase
activity
A previous study reported that monomeric laforin lacks
phosphatase activity and that only laforin dimers possesses
phosphatase activity [28]. In order to determine the effect of
laforin dimerization on its phosphatase activity we utilized two
assays. First, we employed the exogenous substrate para-
nitrophenylphosphate (pNPP) to test the phosphatase activity of
laforin monomer and dimer. When normalized to total protein
content, laforin monomer (peak B in Figure 1A) displayed three
times higher pNPP phosphatase activity compared to laforin dimer
(peak A in Figure 1A) (Figure 2A). This finding is in contrast to the
previous report that dimeric laforin has a higher specific activity
than monomeric laforin [44]. However, we demonstrated in
Figure 1 that the laforin dimer fraction is contaminated with
multiple E. coli proteins, and thus phosphatase activity normalized
for total protein content does not truly represent the phosphatase
activity of the dimer form.
Figure 1. Laforin monomer is abundant compared with its dimer form. (A) The chromatogram is of Hs-laforin-HIS6 purified using a
Superdex-75 column and contains two distinct peaks, peak A and peak B. This is a representative of 6 purifications. (B) Fractions from peak B (65–78)
were collected, concentrated, and re-loaded onto a Superdex-75 column. The chromatograms are representatives of 4 experiments. (C) Proteins from
these peak A (41–43) and B (65–78) were collected, separated using denaturing gel electrophoresis, and stained with Coomassie. (D) The gel bands of
monomeric and dimeric peaks were excised, trypsin digested, and subjected to mass spectrometric identification (MS/MS).
doi:10.1371/journal.pone.0024040.g001
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To account for the E. coli proteins in the dimer fraction, we
normalized both monomer and dimer fractions for laforin content
using a laforin-specific antibody and Western analysis (Figure 2B).
We determined the total protein concentration for the monomer
and dimer fractions, loaded different amounts of each fraction (1–
5 mg for the monomer and 2–10 mg for the dimer), separated the
proteins by SDS-PAGE, Western transferred the proteins, and
probed the blots with an a-HIS6 antibody. We found that the
amount of laforin in the dimeric fraction was decreased by 50% as
compared to the monomeric fraction (Figure 2B). Therefore, 4 mg
of total protein from the dimer fraction only contains 2 mg of
dimeric laforin.
Given the E. coli contamination in the dimer fraction (peak A),
one cannot simply use total protein as a means to assess the
amount of laforin in the dimer fraction. Therefore, we normalized
the dimer fraction so that we analyzed equal amounts of laforin in
the pNPP assay and all subsequent assays. After adjusting for total
laforin amount instead of total protein, we found that the pNPP
phosphatase activity for the laforin monomer and dimer fractions
was equal (Figure 2C). To ascertain that these findings were not
confounded by phosphatase activity that arnA might possess, we
tested and confirmed that arnA lacks in vitro phosphatase activity as
measured by the pNPP assay.
pNPP is a good exogenous substrate to monitor phosphatase
activity, but it does not share structural similarities with glycogen,
a biological substrate of laforin [11,12]. It could be possible that
laforin monomer and dimer differ in their glycogen phosphatase
activity even though their pNPP activity is equal. To test the
glucan phosphatase activity of laforin, we utilized a malachite
green assay where molybdate in malachite green forms a complex
with inorganic phosphate released from a phospho-substrate and
this causes a colorimetric change. Amylopectin is a phosphorylated
glucan that resembles glycogen and is a suitable substrate to
measure glucan phosphatase activity [11]. When normalized for
laforin levels, malachite green assays demonstrated that both
monomer and dimer forms of laforin have equal glucan
phosphatase activity (Figure 2D). Therefore, in contrast to a
previous report, our results demonstrate that both monomeric and
dimeric laforin are equally capable of removing phosphate from
an exogenous substrate and from phospho-glucans.
Oligomerization of glucan phosphatases from other
Kingdoms
Kingdom Plantae/Archaeplastida genomes lack a true ortholog
of laforin, but their genomes do encode for a functional equivalent
of laforin [13]. The Starch EXcess4 gene encodes the SEX4 protein
in Arabidopsis thaliana [45,46]. SEX4 possesses a chloroplast-
Targeting Peptide (cTP), a DSP domain, and a CBM [46,47].
We previously demonstrated that SEX4 is a glucan phosphatase
and human laforin can partially complement mutations in SEX4
[13]. While plants lack a true laforin ortholog, laforin is conserved
in the genome of five protozoans [48]. The most distantly related
laforin ortholog is in the red alga Cyanidioschyzon merolae, Cm-
laforin, which is 25% identical to human laforin [13]. We
previously demonstrated that Cm-laforin possesses the same
biochemical signature as laforin, in that they both bind glucans
and can dephosphorylate phospho-glucans [13]. Given the
functional similarities between human laforin, Cm-laforin, and
SEX4, we used SEX4 and Cm-laforin in the current study to
evaluate if the oligomerization phenomenon is true of all glucan
phosphatases.
We purified SEX4 and Cm-laforin using a similar two-step
purification method that included size exclusion chromatography.
For each protein, we observed that multiple peaks were eluted
from the column, similar as we observed for human laforin (Figure
S1). We analyzed the ratio of SEX4 and Cm-laforin monomer and
dimer fractions via immunoblotting (Figure S2), as was performed
for Hs-laforin in Figure 2B. Then we tested the phosphatase
activity of SEX4 using both pNPP and malachite green assays. We
found that monomeric SEX4 has a slightly higher specific activity
than dimer using both pNPP and malachite green as substrates
(Figure 3A and 3B). For Cm-laforin, the specific activity against
pNPP of the monomer form was three times higher than that of
dimer; whereas the malachite green assay showed that the glucan
phosphatase activity of Cm-laforin was similar for monomer and
dimer (Figure 3C and 3D).
Hs-laforin, SEX4, and Cm-laforin all belong to glucan
phosphatase family [10]. These results demonstrate that glucan
phosphatases from different Kingdoms are all active in the
monomeric form. Interestingly, dimeric forms of glucan phospha-
tases from different Kingdoms exhibit different phosphatase
activity, suggesting different modes of actions for each dimeric
form.
Figure 2. Laforin monomer and dimer have equal phosphatase
activity. (A) Specific activity of laforin monomer (peak B) and dimer
(peak A) fractions obtained by size exclusion chromatography
(Figure 1A) against pNPP. The activities are compared based on total
protein content. (B) A representative immunoblotting image of varying
concentration of laforin monomer and dimer fractions detected using
anti-HIS6 monoclonal antibody. (C) Specific activity for laforin monomer
and dimer fractions against pNPP. The activities are compared based on
total laforin content from the blot in panel B. (D) Phosphate release
measured by malachite green assays using amylopectin as a substrate
for laforin monomer and dimer fractions. Normalization of the activity
was carried out for laforin content. All values are means 6 SEM
(**p,0.001) analyzed by independent sample ‘t’ test.
doi:10.1371/journal.pone.0024040.g002
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Laforin dimerization is affected by redox conditions
Given the difference between our data and a previous report
suggesting that laforin monomer is inactive, we decided to
determine a possible cause for this discrepancy. We found an
interesting result when laforin was stored at 220uC in the absence
of reducing agent. We purified monomeric laforin using Ni-NTA
resin and size-exclusion chromatography by collecting peak B
(Figure 1A), and then stored the purified protein at 220uC in the
presence or absence of a reducing agent (10 mM DTT). These
purified proteins were then reloaded onto an analytical size-
exclusion column (Superdex 200) and, in the case of proteins
stored in the absence of DTT we observed multimeric species that
separated as high molecular weight proteins (larger than
2,000 kDa) (Figure 4A; non-reducing peak). However, proteins
stored in the presence of a reducing agent eluted as a single peak
around 37 kDa (Figure 4A; reducing peak). Thus, monomeric
laforin again remains as a monomer and does not convert into
dimeric laforin similar to our findings in Figure 1B.
The finding that storage of laforin in low levels of DTT is
necessary prompted us to further examine the effect of reducing
agents on laforin oligomerization and phosphatase activity. When
we analyzed the non-reducing peak of laforin (Figure 4A) by gel
electrophoresis under non-reducing conditions (no SDS and no
DTT was present in the sample loading buffer and the samples
were not heated), we observed the presence of laforin monomers,
dimers, and multimers (Figure 4B, first lane). However, if we
added increasing amounts of DTT we found that laforin
oligomerization was reversed and at 100 mM DTT only
monomeric laforin remained (Figure 4B). These results suggest
that laforin oligomerization is very sensitive to oxidation, and that
multiple species of laforin form under non-reducing conditions.
These species may result from intermolecular disulphide bond
formation among the nine cysteine residues present in laforin.
Additionally, these results show that the amount of DTT
commonly utilized in phosphatase assays (1–2 mM DTT) does
not affect dimerization or multimerization. However, these low
levels of DTT are necessary to keep the catalytic cysteine reduced
[49].
Dual specificity phosphatases employ a two-step catalytic
mechanism. After nucleophilic attack of the substrate phosphorus
atom, a phosphoryl-cysteine intermediate is formed before
hydrolysis of the intermediate and release of phosphate
[49,50,51,52]. In oxidative environments, this catalytic cysteine
is modified and inactivated [53]. In order to define the relationship
between oxidation of laforin and its phosphatase activity, we
examined the phosphatase activity of laforin that was purified and
stored in the absence of DTT (non-reducing peak, Figure 4A)
using the exogenous substrate 3-O-methyl fluorescein phosphate
(OMFP). We found that the phosphatase activity of laforin was
dependent on the presence of DTT in the reaction buffer: without
DTT the activity was abolished, whereas in the presence of
10 mM DTT the activity was significantly higher (Figure 4C).
Alternatively, a laforin sample purified and stored in the presence
of DTT (reducing peak, Figure 4A) was fully active, even in the
absence of DTT in the phosphatase reaction buffer (Figure 4C).
These results demonstrate that the phosphatase activity of
monomeric and dimeric laforin is both dependent on a reduced
environment.
In order to further probe the effect of reducing conditions on
laforin dimerization, we analyzed the oligomeric status of laforin in
mammalian HEK293 cells lysed in the presence and absence of
reducing agent. When the cell extracts were prepared in the
absence of DTT, clear monomeric, dimeric, and multimeric
species were resolved by non-reducing gel electrophoresis
(Figure 4D). However, if cells were lysed in the presence of
10 mM DTT (or higher concentrations) only monomeric laforin
was detected. These results suggest that redox conditions may
regulate laforin dimerization and that cellular oxidative stress may
affect laforin oligomerization. It is important to note that these
results strongly suggest that no laforin dimer is present with
$10 mM DTT. The phosphatase assays performed in the
presence of DTT (+ DTT, Figure 4C) employed 10 mM DTT
in the assay buffer. Therefore, all of the laforin present should be
in monomeric form and the monomeric laforin does possess
phosphatase activity, supportive of our findings in Figure 2.
Laforin dimerization does not affect glucan binding
The dimer interface of laforin could involve the carbohydrate-
binding module (CBM), and if so dimerization could provide a
mechanism to modulate glucan-binding. To test whether dimer-
ization of laforin impacts its ability to bind glucans, we utilized a
glucan-binding assay. In this assay, proteins are added to an
amylopectin solution and the mixture undergoes ultracentrifuga-
tion. Proteins in the pellet and supernatant fractions are then
Figure 3. Phosphatase activity of monomeric and dimeric forms of SEX4 and Cm-laforin. (A) Specific activity of SEX4 monomer and dimer
fractions obtained by size exclusion chromatography (Figure S1) against pNPP. The activities are compared based on total SEX4 content (Figure S2).
(B) Phosphate release measured by malachite green assays using amylopectin as a substrate for SEX4 monomer and dimer fractions. The activities are
compared based on total SEX4 content. (C) Specific activity for Cm-laforin monomer and dimer fractions obtained by size exclusion chromatography
(Figure S1) against pNPP. The activities are compared based on total Cm-laforin content (Figure S2). (D) Phosphate release measured by malachite
green assays using amylopectin as a substrate for Cm-laforin monomer and dimer fractions. The activities are compared based on total Cm-laforin
content. All values are means 6 SEM (*p,0.05, **p,0.001) analyzed by one-way ANOVA.
doi:10.1371/journal.pone.0024040.g003
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assessed by Western analysis. Proteins with glucan-binding ability
are retained in the pellet fraction and proteins lacking this ability
are observed in the supernatant fraction. Immunoblotting of the
pellet and supernatant fractions from the glucan-binding assay
Figure 4. Reducing agents prevent laforin oligomer formation.
(A) Gel-filtration analysis on Superdex 200 10/300 GL column of human
laforin stored in the presence or absence of reducing agents (10 mM
DTT). A laforin sample stored at 220uC in the absence of DTT showed
an elution profile (non-reducing peak; squares) corresponding to an
apparent molecular weight higher than 2,000 kDa. A laforin sample
stored in the presence of 10 mM DTT (reducing peak; line) showed an
elution profile corresponding to an apparent molecular weight of
approximately 37 kDa. Calibration of the column with size standards is
indicated; ordinates indicate the natural logarithm (Ln) of molecular
weight (Mr) in kDa. (B) The non-reducing peak of purified laforin was
treated or not with different amounts of DTT before analysis by non-
reducing gel electrophoresis and immunoblotting using anti-laforin
antibodies. The position of the monomeric, dimeric and multimeric
forms of laforin is indicated. (C) Phosphatase activity of the non-
reducing and reducing peaks of laforin was measured in the presence
or absence of 10 mM DTT in the reaction mixture. All values are means
6 SEM (**p,0.01; n: 3) analyzed by independent sample ‘t’ test. (D) Cell
extracts from HEK293 cells transfected with plasmid pCMVmyc-laforin
were analyzed by non-reducing gel electrophoresis. When indicated,
samples were treated with different amounts of DTT before loading
them into the electrophoresis gel. The position of the monomeric,
dimeric and multimeric forms of myc-laforin is indicated.
doi:10.1371/journal.pone.0024040.g004
Figure 5. Dimerization of laforin does not affect its ability to
bind glucans. (A) Equal amounts of monomeric (0.5 mg peak B
fraction, Figure 1A) and dimeric (1 mg peak A fraction, Figure 1A) laforin
were incubated with amylopectin and glucan-binding assay was
performed as described in Methods. A representative image of the I
(input), P (pellet), and S (supernatant) fractions analyzed by Western
blotting is presented. (B) The OMFP phosphatase activity of GST-laforin
fusion protein purified from bacteria was measured in the presence of
different amounts of glycogen in the reaction mixture. We assigned the
maximal phosphatase activity in the absence of glycogen as 100% and
then compared activity in the presence of glycogen to this maximal
amount. (C) Phosphatase activity of GST-laforin and GST-VHR in the
absence or presence of glycogen (0.5 mg/ml) in the reaction mixture.
As in Figure B, we assigned maximal phosphatase activities as 100% and
compared activities in the presence of glycogen to the untreated
samples (control). Values are means 6 SEM of three independent
experiments (*p,0.05) analyzed by independent sample ‘t’ test.
doi:10.1371/journal.pone.0024040.g005
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showed that both laforin monomer and dimer bind to amylopectin
and are enriched in the pellet fraction (Figure 5A). Therefore,
dimerization of laforin does not inhibit its glucan-binding.
Multiple groups have reported that glycogen inhibits laforin
phosphatase activity [54,55,56]. In agreement with these results,
we observed a clear inhibition of monomeric laforin phosphatase
activity in response to higher levels of glycogen in the reaction
mixture (Figure 5B). Similarly, we found that glycogen inhibits the
phosphatase activity of dimeric laforin (Figure 5B). As expected,
glycogen did not affect the phosphatase activity of VHR
(Figure 5C), a dual specificity phosphatase that lacks a CBM.
Therefore, glycogen inhibits the phosphatase activity of mono-
meric and dimeric laforin.
Laforin dimerization does not affect its association to
malin but the presence of malin differentially affects
glucan-binding of monomer and dimer
As discussed in the introduction, laforin forms a functional
complex by associating with malin and this complex is involved in
ubiquitination and proteasomal degradation of multiple proteins
involved in glycogen metabolism [21,22,24,25]. The differences in
the structure of monomeric and dimeric laforin could alter its
ability to interact with malin that could change the scaffolding
function of laforin. Therefore, we investigated the ability of malin
to interact with monomeric or dimeric laforin by co-immunopre-
cipitation. We transfected HEK293 cells with FLAG-tagged
malin, lysed the cells, immunoprecipitated FLAG-malin with
anti-FLAG M2 agarose beads, and washed the beads multiple
times. We then incubated the bound FLAG-malin with mono-
meric or dimeric laforin, again washed the beads, eluted bound
proteins with NuPage sample buffer, and analyzed the proteins by
Western analysis. We observed that malin interacted with both
monomeric and dimeric laforin to equal degrees (Figure 6A).
Thus, laforin dimerization does not impair its interaction with
malin.
Given that malin and laforin form a complex, we decided to test
the activity of monomeric and dimeric laforin in the presence of
malin using the malachite green assay. The presence of malin did
not affect the phosphatase activity of either monomeric or dimeric
laforin (Figure 6B). Thus, both forms maintain phosphatase
activity in the presence of malin.
Although there was no change in the ability of monomeric and
dimeric laforin to bind malin, we surmised that the binding of
malin with laforin could have a differential impact on glucan-
binding. To determine how monomeric and dimeric laforin
interact with glucans in the presence of malin, we incubated equal
amounts of GST-malin-HIS6 with both forms of laforin and then
performed the glucan-binding assay as described above. The
presence of malin decreased the binding of monomeric laforin to
glucans as indicated by the presence of monomeric laforin in both
the pellet and supernatant fractions (Figure 6C). However, the
presence of malin only minimally decreased the binding of dimeric
laforin to amylopectin (Figure 6C). Thus, the ability of dimeric
laforin to bind glucans is not impaired by malin. These data
suggest that monomeric laforin binds to malin and that the laforin-
malin complex does not bind as tightly to glucans as laforin
monomer alone.
Discussion
Defining laforin dimerization is necessary to evaluate the
functional and pathological role of laforin in Lafora disease. In
the present study, we demonstrate that monomeric laforin is the
most abundant form of the phosphatase under normal reduced
conditions. Our study also establishes that laforin phosphatase
activity is similar for both monomer and dimer species. In
addition, monomeric and dimeric laforin exhibit equal ability to
associate with malin and bind glucans. However, monomeric
laforin has decreased glucan-binding capacity in the presence of
malin, while the glucan binding of dimeric laforin is not affected
by malin. Another key finding of this study is that oxidative
conditions play a key role in both the phosphatase activity and
oligomerization of laforin. These results demonstrate that lack of a
reducing agent drives laforin oligomerization and abolishes the
phosphatase activity of laforin. Conversely, the presence of
glycogen did not impact laforin oligomerization, but glycogen
did decrease its phosphatase activity. Cumulatively, our data
establish that monomeric and dimeric laforin possess similar
phosphatase activity, glucan binding, and dimerization is en-
hanced by increased oxidation and that glucan binding in the
presence of malin is decreased for monomeric laforin and not for
the dimer.
Most primary papers and reviews on Lafora disease have
formulated hypotheses with the assumption that mutations
inactivating monomeric laforin give rise to Lafora disease.
Figure 6. Dimerization of laforin does not affect its ability to
associate with malin. (A) Equal amount of monomeric and dimeric
laforin used in section A of Figure 6, were mixed with FLAG-malin and
immunoprecipitation was carried out as described in Methods. A
representative image showing detection of monomeric and dimeric
laforin in samples immunoprecipitated using anti-Flag agarose beads is
presented. (B) Phosphatase activity of monomeric and dimeric laforin in
the presence of malin was determined using amylopectin as substrate.
(C) Representative image demonstrating the presence in the I (input), P
(pellet), and S (supernatant) fractions from the glucan-binding assay of
laforin monomer (0.5 mg) and dimer (1.0 mg), that had been previously
mixed with Hs-malin-HIS6 (1.0 mg). The membrane was blotted with a-
laforin antibody.
doi:10.1371/journal.pone.0024040.g006
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However, a recent study reported that monomeric laforin lacks
phosphatase activity [28]. Thus, one of the key reasons to initiate
this work was to determine if monomeric laforin possesses
phosphatase activity, and if not then to re-assess our understanding
of disease mutations. We utilized multiple lines of evidence to
definitively demonstrate monomeric laforin is an active phospha-
tase: 1) monomeric laforin purified via Ni-NTA resin and resolved
using size exclusion chromatography possesses pNPP activity
(Fig. 2C); 2) the same monomeric laforin also possesses activity
against the phospho-glucans, a biologically relevant substrate
(Fig. 2D); 3) monomeric SEX4 from Arabidopsis possesses
phosphatase activity against pNPP and a phospho-glucan
(Fig. 3A and B); 4) monomeric laforin from the red algae C.
merolae possesses phosphatase activity against pNPP and a
phospho-glucan (Fig. 3C and D); and 5) when DTT levels are
increased to $10 mM DTT only monomeric laforin exists
(Fig. 4D) and Figure 4C demonstrates that laforin is fully active
under these conditions. The above results clearly demonstrate that
monomeric laforin is the most abundant form of laforin and that it
contains full phosphatase activity. The lack of phosphatase activity
of monomeric laforin reported by Liu et al. [44] is possibly due to
the absence of reducing agents either during purification and/or
storage.
Hs-laforin, Cm-laforin, and SEX4 all contain a CBM and DSP
domain and all belong to the newly discovered class of glucan
phosphatases [10,11,13]. To define how dimerization affects other
glucan phosphatases, we purified both Cm-laforin and SEX4 and
tested their pNPP and glucan phosphatase activity. Similar to Hs-
laforin, SEX4 and Cm-laforin both formed dimers. Contrary to
what we observed for Hs-laforin, the phosphatase activity of the
monomeric SEX4 and Cm-laforin was higher than the dimeric
form. These data indicate that glucan phosphatases are functional
in their monomeric state, but that differences are present across
Kingdoms.
Our results from cell culture suggest that laforin dimerization
may be a dynamic process. The sensitivity of the oligomeric-
monomeric transition to the presence of reducing agents indicates
that inter-molecular Cys-Cys bridges play a key role in oligomer
formation. These data suggests that laforin is present in vivo as a
combination of monomeric and oligomeric forms, and changes in
the cellular reducing conditions may regulate the transition from
one state to the other. In support of this hypothesis, a recent paper
found that a laforin mutation, laforin-Ser25Ala, is unable to
interact with itself in both a yeast two-hybrid system and in
mammalian cell culture experiments [57].
We found that both monomeric and dimeric laforin bind
glucans with equal affinity. This finding suggests that sites involved
in laforin dimerization do not affect the conformation of essential
CBM residues involved in glucan-binding. Next, we analyzed the
inhibitory role of glycogen on laforin phosphatase activity. We
observed that this inhibitory role is not due to alterations in the
oligomeric-monomeric transition, as the presence of glycogen did
not affect oligomer formation. Moreover, a dual specificity
phosphatase lacking a carbohydrate-binding domain (VHR) was
resistant to glycogen inhibition. Therefore, our results suggest that
glycogen either induces a conformational change in laforin
structure or inhibits phosphatase activity because it blocks the
entry of substrates to the phosphatase catalytic site.
In addition to phosphatase activity, we analyzed laforin
monomer and dimer for their ability to interact with malin. The
equal association of monomeric and dimeric laforin with malin
suggests that both forms possess active scaffolding function and
form laforin-malin complexes. Phosphatase activity of laforin
monomer and dimer was not affected by presence of malin, which
suggests that laforin-malin complex is functionally active. While
we did not observe a difference in glucan-binding between the two
forms, we did observe a difference when malin was present. Malin
affected the glucan-binding of only monomeric laforin and did not
affect glucan-binding of the dimer form.
In conclusion, our findings establish that monomeric laforin is
an active enzyme, and that laforin dimerization is not essential for
its physiological activity. In addition, we found that monomer and
dimer possess equal specific activity in removing phosphate from
both generic and biologically relevant substrates. Our in vitro
results and previous in vivo data clearly demonstrate that
monomeric laforin is far more abundant than the dimer and that
changes in the cellular reducing conditions may regulate the
transition from one state to the other. These results are especially
germane in terms of defining the form(s) of laforin that is most
relevant to the etiology of Lafora disease.
Supporting Information
Figure S1 Purification of Arabidopsis Starch EXcess4
(SEX4) and C. merolae laforin (Cm-laforin). (A) The
32 kDa SEX4 protein was purified in a similar manner as Hs-
laforin. The chromatogram is of SEX4-HIS6 purified using a
Superdex-75 and contains three distinct peaks. This is a
representative of 5 purifications. (B) The 74 kDa Cm-laforin
protein was purified in a similar manner as Hs-laforin. The
chromatogram is of Cm-laforin-HIS6 purified using a Superdex-
200 and contains three distinct peaks. This is a representative of 4
purifications.
(EPS)
Figure S2 Quantification of monomer versus dimer of
SEX4 and Cm-laforin. (A) A representative immunoblotting
image of varying concentration of SEX4 monomer and dimer
fractions detected using anti-HIS6 monoclonal antibody. (B) A
representative immunoblotting image of varying concentration of
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